Related Experiment Video
Updated: Sep 26, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Using Circulating Tumor DNA To Guide Adjuvant Therapy in Bladder Cancer: IMvigor010 and IMvigor011
Camilla M Grunewald1, Guenter Niegisch1, Peter Albers2
1Department of Urology, University Hospital, Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.
Abstract:
Recent data from IMvigor010 impressively demonstrate the potential of circulating tumor DNA (ctDNA) as a prognostic and a predictive biomarker in patients with urothelial carcinoma. Although ctDNA status was prospectively assessed, the published data are only exploratory and require further prospective validation. Results from the IMvigor011 trial are therefore eagerly awaited.

